The FDA extended its review of Exelixis’ colorectal cancer drug candidate after the company submitted additional safety and efficacy data related to its potential treatment of metastatic colorectal cancer (mCRC). The review clock was pushed by three months. The company’s additional dataset indicates an active regulatory dialogue as Exelixis works to address evidentiary gaps around benefit-risk, positioning, and supporting analyses. For biotech stakeholders, the move underscores how supplementary submissions can affect timing and market expectations in oncology programs where approval decisions are closely watched.